Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tycho Baumann

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Expert Opinion on Pharmacotherapy|February 25, 2014
New treatment options for chronic lymphocytic leukemiaJulio Delgado, Tycho Baumann, Rodrigo Santacruz, et al.
Current Pharmaceutical Design|May 18, 2012
Chronic lymphocytic leukemia therapy: beyond chemoimmunotherapyJulio Delgado, Tycho Baumann, Gabriela Ghita, et al.
Blood|August 26, 2010
Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significanceCarol Moreno, Kate Hodgson, Gerardo Ferrer, et al.
Leukemia & Lymphoma|January 5, 2013
MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemiaGerardo Ferrer, Alfons Navarro, Kate Hodgson, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 16, 2013
Rituximab-based chemoimmunotherapy prolongs survival of patients with chronic lymphocytic leukemia independently of the time of administrationJulio Delgado, Gabriela Ghita, Tycho Baumann, et al.
Leukemia Research|September 4, 2012
Retreatment with purine analogs in patients with chronic lymphocytic leukemiaIvan Dlouhy, Gabriela Ghita, Tycho Baumann, et al.
American Journal of Hematology|January 26, 2017
Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPIJulio Delgado, Michael Doubek, Tycho Baumann, et al.
Leukemia & Lymphoma|June 29, 2011
Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemiaGerardo Ferrer, Kate Hodgson, Arturo Pereira, et al.
British Journal of Haematology|November 13, 2015
CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV statusTycho Baumann, Julio Delgado, Rodrigo Santacruz, et al.
Leukemia|February 5, 2021
Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patientsTycho Baumann, Riccardo Moia, Gianluca Gaidano, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Expert Opinion on Pharmacotherapy|February 25, 2014
New treatment options for chronic lymphocytic leukemiaJulio Delgado, Tycho Baumann, Rodrigo Santacruz, et al.
Current Pharmaceutical Design|May 18, 2012
Chronic lymphocytic leukemia therapy: beyond chemoimmunotherapyJulio Delgado, Tycho Baumann, Gabriela Ghita, et al.
Blood|August 26, 2010
Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significanceCarol Moreno, Kate Hodgson, Gerardo Ferrer, et al.
Leukemia & Lymphoma|January 5, 2013
MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemiaGerardo Ferrer, Alfons Navarro, Kate Hodgson, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 16, 2013
Rituximab-based chemoimmunotherapy prolongs survival of patients with chronic lymphocytic leukemia independently of the time of administrationJulio Delgado, Gabriela Ghita, Tycho Baumann, et al.
Leukemia Research|September 4, 2012
Retreatment with purine analogs in patients with chronic lymphocytic leukemiaIvan Dlouhy, Gabriela Ghita, Tycho Baumann, et al.
American Journal of Hematology|January 26, 2017
Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPIJulio Delgado, Michael Doubek, Tycho Baumann, et al.
Leukemia & Lymphoma|June 29, 2011
Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemiaGerardo Ferrer, Kate Hodgson, Arturo Pereira, et al.
British Journal of Haematology|November 13, 2015
CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV statusTycho Baumann, Julio Delgado, Rodrigo Santacruz, et al.
Leukemia|February 5, 2021
Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patientsTycho Baumann, Riccardo Moia, Gianluca Gaidano, et al.
Pageof 6